High Cholesterol Gone with One Treatment?
Base editing technology is moving beyond rare diseases to potentially eliminate high cholesterol with a single, highly precise genetic intervention. A profound paradigm shift from lifelong daily disease management to permanent, proactive prevention. Read about it this week in the Guardrail, The Power of Gene Editing
By Michael Bronfman
September 14, 2026
Imagine going to the clinic for a single shot and fixing your high cholesterol for the rest of your life. For millions of people worldwide, this sounds almost like magic. However, new medical progress is turning this dream into real science.
In mid 2025, A major pharmaceutical company bought out a smaller biotechnology company called Verve Therapeutics. In order to gain control of some advanced genetic tools. The main focus of this effort is a new experimental drug called VERVE 102.1.1
This drug uses a super precise technology called base editing. Unlike older ways of fixing genes, base editing acts like a tiny spell checker for your DNA. Instead of cutting the DNA strand completely, it neatly changes one single genetic letter. VERVE 102 targets a specific liver gene called PCSK9. By turning off this single gene, the body can clear bad cholesterol from the blood much faster.
As Phase 2 clinical trials expand, scientists and doctors are closely examining how this technology works. They are looking at what makes it safe and how it could completely change how we treat common long-term health conditions.
Understanding the Danger of High Cholesterol
To see why this new treatment is such a big deal, we first need to understand how cholesterol harms the human body.
Your body needs some cholesterol to build healthy cells. But too much of one specific type, called low-density lipoprotein (LDL) cholesterol, creates serious trouble. People often call LDL “bad cholesterol.” When you have high levels of LDL floating through your bloodstream for many years, it builds up inside the walls of your arteries. This buildup turns into hard spots called plaque.
Over time, plaque narrows and stiffens your blood vessels. This condition is known as atherosclerosis. When arteries get clogged, blood cannot flow easily to vital organs. If a piece of plaque breaks open, a blood clot can form quickly. This blockage can cause a sudden heart attack or a stroke. Cardiovascular disease remains the number one cause of death worldwide.
Many people try to lower their bad cholesterol by eating healthy food and exercising regularly. While lifestyle changes are important, they are often not enough. Many people have genes that make their bodies produce far too much cholesterol, no matter what they eat.
For decades, doctors have relied on daily pills called statins. Statins work well for millions of people, but only if they take them every single day. Many patients struggle to take a pill every day for the rest of their lives. Some people experience muscle pain or other side effects from statins. Others take their daily medication, but their bad cholesterol still stays at dangerous levels.
This gap in results is why scientists have been searching for a better, longer-lasting solution.
How PCSK9 Controls Your Cholesterol
To lower cholesterol permanently, scientists had to find the biological switch that controls it in the liver. They found that switch in a protein named PCSK9.
Your liver cells have small receptors on their surface that act like tiny nets. These receptors catch bad LDL cholesterol as it flows through the blood and pull it inside the liver cell to be broken down. After dropping off the cholesterol, the receptor returns to the cell surface to catch more. This recycling system keeps your blood clean.
This is where the PCSK9 protein comes in. PCSK9 binds to those cholesterol receptors and stops them from recycling. Instead of sending the receptor back to the surface, PCSK9 causes the cell to destroy the receptor inside.
When your body makes a lot of PCSK9, you have fewer receptors on your liver cells. Fewer receptors mean bad cholesterol stays in your blood longer.
When your body makes very little PCSK9, your liver cells recycle their receptors over and over again. This pulls huge amounts of bad cholesterol out of your bloodstream.
Years ago, researchers made a surprising discovery while studying people with rare genetic mutations. They found individuals who were born with a broken PCSK9 gene. These people naturally made almost no PCSK9 protein. Surprisingly, they were completely healthy, had extremely low bad cholesterol levels, and almost never developed heart disease.
This discovery proved that humans do not need active PCSK9 to live a healthy life. It gave scientists a clear goal. If they could turn off the PCSK9 gene in adults, they could permanently protect them from heart attacks.
The Evolution of Gene Editing: From Scissors to Spell Checkers
Early attempts to edit human genes used a famous tool called CRISPR-Cas9. Think of original CRISPR as a pair of molecular scissors. It finds a specific spot in your DNA and cuts clear through both strands of the double helix.
While cutting DNA can turn off a faulty gene, “double-strand breaks” bring some risks. When a cell tries to glue the two cut ends of DNA back together, it can sometimes make mistakes. It might accidentally delete a small section of DNA or rearrange pieces erroneously. When treating millions of people for a common illness, doctors need tools that are as safe and precise as possible.
This need for safety led to the innovation of base editing. Developed by researchers like David Liu at Harvard University, base editing is a major leap forward in genetic medicine.2
This need for safety led to the innovation of base editing. Developed by researchers like David Liu at Harvard University, base editing is a major leap forward in genetic medicine.2
Instead of cutting the DNA completely, a base editor works like a pencil and eraser. DNA is made of four chemical bases represented by the letters A, C, G, and T. A base editor travels to a specific spot in the DNA, opens the double strand gently without breaking it, and chemically changes one letter into another.
In VERVE 102, the base editor targets the PCSK9 gene in liver cells. It changes a single A letter to a G letter. This tiny, single-letter change alters the biological instructions just enough to stop the liver cell from producing the PCSK9 protein entirely. Because there are no double-strand cuts, the risk of accidental genetic damage drops significantly.
Inside the Treatment: Delivery via Lipid Nanoparticles
Having a clever genetic editor in a test tube is only half the battle. The biggest challenge in genetic medicine has always been delivery. How do you get the base editor inside millions of liver cells inside a living human body without causing harm?
They are solving this by using tiny spheres of fat called lipid nanoparticles, or LNPs. If you received an mRNA vaccine for COVID-19, you are already familiar with lipid nanoparticles. They act like microscopic protective bubbles that carry fragile genetic instructions safely through the bloodstream.
Here is how the treatment works step by step:
- The Dose Preparation: The treatment contains two main components packaged inside the lipid nanoparticle. The first is messenger RNA that tells the cell how to build the base editing protein. The second is a guide RNA that acts like a GPS map, showing the protein exactly where to find the PCSK9 gene. 2.** Simple Infusion:** The patient receives the drug through a simple intravenous, or IV, line in their arm during a standard clinic visit. No surgery, bone marrow removal, or complex hospital stays are required.
- Liver Targeting: The lipid nanoparticles are specially designed with surface molecules that naturally attract them to liver cells. Once injected, they travel through the blood straight to the liver.
- Cell Entry: The liver cells absorb the lipid nanoparticles. Inside the cell, the lipid bubble dissolves, releasing the genetic instructions.
- The Edit: The liver cell uses the mRNA to build the base editor protein. Guided by the guide RNA, the editor enters the cell nucleus, finds the PCSK9 gene, and makes the single-letter change.
- Clean Departure: Once the edit is made, the editor protein and the lipid nanoparticle naturally break down and disappear from the body within a few days. But the change to the DNA remains permanent. Whenever that liver cell divides, its daughter cells inherit the edited, non-working version of the PCSK9 gene.3
Clinical Trial Results and What the Science Shows
The excitement surrounding VERVE 102 comes directly from real clinical data collected in human trials.
Earlier clinical studies testing the first version of this concept showed that base editing could dramatically lower PCSK9 protein levels in humans. However, early delivery methods caused temporary side effects, leading researchers to refine the lipid nanoparticle shell. The updated formulation, VERVE 102, was designed to be gentler on the body while delivering the same powerful genetic edit.
Recent clinical updates show impressive outcomes:
Dramatic Cholesterol Drop: Patients receiving a single high dose of VERVE 102 saw their bad LDL cholesterol levels fall by over 50 to 60 percent.
PCSK9 Shutdown: Measurement of the PCSK9 protein in the blood showed a drop of up to 88 percent, showing that the base editor successfully turned off the targeted gene in most liver cells.
Durable Impact: Follow-up data showed that the reduction in bad cholesterol remained steady over time. Because the edit is made directly to the cell's DNA, the liver continues to produce low cholesterol levels month after month without needing additional doses.
Shifting from Acute Care to Chronic Prevention
For decades, the standard model of medicine has been reactive care. We wait until a person develops high cholesterol or suffers a minor heart event, and then we prescribe a daily pill that they must take for thirty or forty years.
This model has major flaws. First, human behavior is imperfect. Studies show that within one year of being prescribed a daily statin, up to half of all patients stop taking their medication regularly. Life gets busy, prescriptions expire, pills are expensive, and side effects cause people to quit. Every day a patient skips their medication, their risk of a heart attack creeps back up.
Second, chronic care costs healthcare systems a lot. Decades of doctor visits, blood tests, and daily drug refills cost insurance companies, governments, and patients thousands of dollars per year.
Base editing introduces a completely new way of thinking about chronic disease. Scientists call it the "one and done" paradigm. Instead of managing a disease over a lifetime with thousands of pills, a patient receives a single therapeutic intervention that fixes the root cause forever.
If successful in broader Phase 2 and eventual Phase 3 trials, VERVE 102 could transform cardiovascular care from a lifelong burden into a single, proactive medical visit.
Safety and Regulatory Considerations
While the promise of base editing is huge, safety remains the top concern for doctors and regulators alike. When you take a daily pill, you can stop taking it if you experience bad side effects. But when you edit a person's DNA, you cannot hit an undo button. The change is permanent.
Because of this, researchers monitor clinical trial participants very closely for two primary risks:
Off-target Editing
An off-target edit happens if the guide RNA accidentally directs the base editor to the wrong spot in the genome. If the tool alters a healthy, important gene elsewhere in the cell, it could lead to unexpected health problems, including cancer. To prevent this, scientists use advanced computer modeling and deep sequencing to test millions of DNA sites, ensuring the guide RNA only binds to the target gene.
Liver Health and Inflammation
Because the drug delivers lipid nanoparticles directly to the liver, doctors must monitor patients for liver inflammation or temporary spikes in liver enzymes. Clinical trials track blood tests closely after the infusion to verify that the liver remains healthy and functions normally.
Regulatory bodies like the FDA require gene editing candidates to undergo years of careful tracking. Patients in early trials are followed for up to fifteen years to confirm that the editing remains safe and effective over long periods.
Expanding Beyond Cholesterol
Big pharmaceutical companies believe gene editing is ready for common conditions.
In the past, gene therapy was reserved almost exclusively for rare, deadly genetic conditions like sickle cell disease or spinal muscular atrophy. These conditions affect small numbers of people who have no other treatment options. Because the conditions are severe, regulators and patients are willing to accept higher costs and risks. Eli Lilly's acquisition of Verve Therapeutics in mid-2025 signals a major shift away from that model.
High cholesterol affects tens of millions of adults worldwide. By bringing base editing to hyperlipidemia, they are testing whether genetic medicine can scale up to treat common public health problems.
If base editing works safely for high cholesterol, the same platform can be adapted to treat many other long-term health issues:
- High Triglycerides: Editing genes like ANGPTL3 to lower dangerous blood fats.
- Hypertension: Targeting genes involved in blood pressure regulation to permanently lower high blood pressure.
- Type 2 Diabetes: Editing specific liver or pancreas pathways to improve how the body responds to insulin.
- Liver Disease: Turning off genes that cause fat accumulation or scarring in the liver. 4
The Path Ahead
The journey of VERVE 102 through clinical trials is one of the most exciting stories in modern medicine. It represents a shift in how humanity approaches human health. We are moving away from treating symptoms with daily chemicals and moving toward fixing the underlying source code of human disease.
Important questions remain to be answered over the coming years. Will insurance companies cover the upfront cost of a one-time gene editing treatment? How long will the cholesterol-lowering effect last in humans over twenty or thirty years? Will broader trials confirm that side effects remain minimal?
As Phase 2 trials continue to gather data, the scientific world is watching closely. If the results hold true, we may be standing at the beginning of an era where heart attacks become a preventable worry of the past, defeated by a single, precise genetic edit.
Navigating complex regulatory expectations, quality systems, and clinical trial oversight is vital, as gene therapies and advanced precision technologies scale toward mass markets. Contact Metis Consulting Services
Footnotes:
You can read more about how lipid nanoparticles deliver therapies by visiting the National Institutes of Health website.
To explore ongoing research in genetic science and biotechnology, you can visit the World Health Organization website.
To learn more about how clinical trials are designed and monitored for safety, check out the educational resources on the US Food and Drug Administration website.
